{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:33:32Z","timestamp":1791387212313,"version":"4.3.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00210-025-04388-1","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T09:25:05Z","timestamp":1753176305000},"page":"889-901","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Extended reduced versus full-dose treatment with factor Xa inhibitors in patients with venous thromboembolism: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"399","author":[{"given":"Umama","family":"Alam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Abdullah","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ansab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4273-0827","authenticated-orcid":false,"given":"Shree","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fazia","family":"Khattak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaryab","family":"Bacha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiza Tooba","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Sajjad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Afridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarar Ahmad Khan","family":"Afridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Moiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheel","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"4388_CR1","doi-asserted-by":"publisher","unstructured":"Agnelli G, Buller HR, Cohen A et al. (2013) Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368:699\u2013708. https:\/\/doi.org\/10.1056\/nejmoa1207541","DOI":"10.1056\/nejmoa1207541"},{"key":"4388_CR2","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s11239-015-1310-7","volume":"41","author":"AE Burnett","year":"2016","unstructured":"Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J (2016J) Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 41:206\u2013232","journal-title":"J Thromb Thrombolysis"},{"key":"4388_CR3","unstructured":"Cochrane handbook for systematic reviews of interventions | Cochrane Training [Internet]. [cited 2025 Jan 11]. Available from: https:\/\/training.cochrane.org\/handbook"},{"issue":"12","key":"4388_CR4","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1161\/CIRCRESAHA.121.318225","volume":"128","author":"ME Colling","year":"2021","unstructured":"Colling ME, Tourdot BE, Kanthi Y (2021J 11) Inflammation, infection and venous thromboembolism. Circ Res 128(12):2017\u20132036","journal-title":"Circ Res"},{"issue":"8","key":"4388_CR5","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.3390\/jcm13082394.PMID:38673665;PMCID:PMC11051129","volume":"13","author":"L Costanzo","year":"2024","unstructured":"Costanzo L, Di Paola F, Pedi AM, Failla G, Mangiafico M (2024A 19) Long-term efficacy and safety of direct oral anticoagulants at reduced doses in the secondary prevention of venous thromboembolism and post-thrombotic syndrome. J Clin Med 13(8):2394. https:\/\/doi.org\/10.3390\/jcm13082394.PMID:38673665;PMCID:PMC11051129","journal-title":"J Clin Med"},{"key":"4388_CR6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/s0140-6736(24)02842-3","volume":"405","author":"F Couturaud","year":"2025","unstructured":"Couturaud F, Schmidt J, Sanchez O et al (2025) Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial. The Lancet 405:725\u2013735. https:\/\/doi.org\/10.1016\/s0140-6736(24)02842-3","journal-title":"The Lancet"},{"key":"4388_CR7","doi-asserted-by":"crossref","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled clinical trials [Internet]. 1986 [cited 2025 Jan 11];7(3):177\u201388. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/3802833\/","DOI":"10.1016\/0197-2456(86)90046-2"},{"issue":"10063","key":"4388_CR8","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1016\/S0140-6736(16)30514-1","volume":"388","author":"M Di Nisio","year":"2016","unstructured":"Di Nisio M, van Es N, B\u00fcller HR (2016D 17) Deep vein thrombosis and pulmonary embolism. Lancet 388(10063):3060\u20133073. https:\/\/doi.org\/10.1016\/S0140-6736(16)30514-1","journal-title":"Lancet"},{"key":"4388_CR9","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed) [Internet]. 2003 Sep 6 [cited 2025 Jan 11];327(7414):557\u201360. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12958120\/","DOI":"10.1136\/bmj.327.7414.557"},{"issue":"19","key":"4388_CR10","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1001\/archinternmed.2010.367","volume":"170","author":"A Iorio","year":"2010","unstructured":"Iorio A, Kearon C, Filippucci E, Marcucci M, Macura A, Pengo V, Siragusa S, Palareti G (2010O 25) Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med 170(19):1710\u20131716. https:\/\/doi.org\/10.1001\/archinternmed.2010.367","journal-title":"Arch Intern Med"},{"issue":"9","key":"4388_CR11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jamainternmed.2013.122","volume":"173","author":"SA Johannesdottir","year":"2013","unstructured":"Johannesdottir SA, Horv\u00e1th-Puh\u00f3 E, Dekkers OM et al (2013) Use of glucocorticoids and risk of venous thromboembolism. JAMA Intern Med 173(9):743\u2013752","journal-title":"JAMA Intern Med"},{"key":"4388_CR12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa035422","volume":"349","author":"C Kearon","year":"2003","unstructured":"Kearon C, Ginsberg JS, Kovacs MJ et al (2003) Comparison of low intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 349:631\u2013639","journal-title":"N Engl J Med"},{"issue":"10294","key":"4388_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(20)32658-1","volume":"398","author":"F Khan","year":"2021","unstructured":"Khan F, Tritschler T, Kahn SR, Rodger MA (2021J 3) Venous thromboembolism. The Lancet 398(10294):64\u201377","journal-title":"The Lancet"},{"issue":"38","key":"4388_CR14","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 37(38):2893\u20132962","journal-title":"Eur Heart J"},{"issue":"5","key":"4388_CR15","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.cgh.2014.11.007","volume":"13","author":"A Lanas","year":"2015","unstructured":"Lanas A, Carrera-Lasfuentes P, Arguedas Y et al (2015) Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol 13(5):906\u2013912","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"4388_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s11239-023-02842-6","volume":"56","author":"S Ligia","year":"2023","unstructured":"Ligia S, Musiu P, Serrao A et al (2023) Low-dose apixaban or rivaroxaban as secondary prophylaxis of upper extremity deep vein thrombosis. J Thromb Thrombolysis 56(2):323\u2013326. https:\/\/doi.org\/10.1007\/s11239-023-02842-6","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"4388_CR17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41569-022-00787-6","volume":"20","author":"PL Lutsey","year":"2023","unstructured":"Lutsey PL, Zakai NA (2023A) Epidemiology and prevention of venous thromboembolism. Nat Rev Cardiol 20(4):248\u2013262","journal-title":"Nat Rev Cardiol"},{"key":"4388_CR18","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2416112","author":"I Mah\u00e9","year":"2025","unstructured":"Mah\u00e9 I, Carrier M, Mayeur D et al (2025) Extended reduced-dose apixaban for cancer-associated venous thromboembolism. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa2416112","journal-title":"N Engl J Med"},{"key":"4388_CR19","doi-asserted-by":"publisher","unstructured":"McBane RD, Loprinzi CL, Zemla T, et al. (2024) Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial. Journal of Thrombosis and Haemostasis; 22:1704\u201314. https:\/\/doi.org\/10.1016\/j.jtha.2024.03.011.","DOI":"10.1016\/j.jtha.2024.03.011"},{"issue":"21","key":"4388_CR20","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","volume":"381","author":"R Mehran","year":"2019","unstructured":"Mehran R, Baber U, Sharma SK et al (2019) Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med 381(21):2032\u20132042","journal-title":"N Engl J Med"},{"issue":"22","key":"4388_CR21","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1001\/archinte.164.21.2367","volume":"164","author":"WE Meijer","year":"2004","unstructured":"Meijer WE, Heerdink ER, Nolen WA et al (2004) Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 164(22):2367\u20132370","journal-title":"Arch Intern Med"},{"issue":"19","key":"4388_CR22","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1001\/jama.2008.656","volume":"300","author":"SR Nalluri","year":"2008","unstructured":"Nalluri SR, Chu D, Keresztes R et al (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients. JAMA 300(19):2277\u20132285","journal-title":"JAMA"},{"key":"4388_CR23","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2021 Mar 29 [cited 2025 Jan 11];372. Available from: https:\/\/www.bmj.com\/content\/372\/bmj.n71"},{"issue":"4","key":"4388_CR24","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.3390\/ijms24043169","volume":"24","author":"D Pastori","year":"2023","unstructured":"Pastori D, Cormaci VM, Marucci S, Franchino G, Del Sole F, Capozza A, Fallarino A, Corso C, Valeriani E, Menichelli D, Pignatelli P (2023F 5) A comprehensive review of risk factors for venous thromboembolism: from epidemiology to pathophysiology. Int J Mol Sci 24(4):3169","journal-title":"Int J Mol Sci"},{"issue":"23","key":"4388_CR25","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1093\/eurheartj\/ehr373","volume":"32","author":"C Patrono","year":"2011","unstructured":"Patrono C, Morais J, Baigent C et al (2011) Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 32(23):2922\u20132932","journal-title":"Eur Heart J"},{"key":"4388_CR26","unstructured":"Pharmaceutical Journal. Standard-dose factor Xa inhibitors not necessarily better than reduced dose, study results suggest [Internet]. 2024 Apr 29 [cited 2025 May 9]. Available from: https:\/\/pharmaceutical-journal.com\/article\/news\/standard-dose-doacs-not-necessarily-better-than-reduced-dose-study-results-suggest"},{"key":"4388_CR27","doi-asserted-by":"crossref","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR. RoB 2: (2019) a revised tool for assessing risk of bias in randomised trials. bmj., 366","DOI":"10.1136\/bmj.l4898"},{"issue":"20","key":"4388_CR28","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1056\/NEJM200105173442007","volume":"344","author":"JP Vandenbroucke","year":"2001","unstructured":"Vandenbroucke JP, Rosing J, Bloemenkamp KW et al (2001) Oral contraceptives and the risk of venous thrombosis. N Engl J Med 344(20):1527\u20131535","journal-title":"N Engl J Med"},{"issue":"9","key":"4388_CR29","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1111\/jth.15427","volume":"19","author":"L Vasanthamohan","year":"2021","unstructured":"Vasanthamohan L, Boonyawat K, Chai-Adisaksopha C, Crowther M (2021S) Reduced-dose direct oral anticoagulants (DOACs) in the extended treatment of venous thromboembolism: a systematic review and meta-analysis\u2014response to commentary. J Thromb Haemost 19(9):2359\u20132360","journal-title":"J Thromb Haemost"},{"key":"4388_CR30","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/nejmoa1700518","volume":"376","author":"JI Weitz","year":"2017","unstructured":"Weitz JI, Lensing AWA, Prins MH et al (2017) Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 376:1211\u20131222. https:\/\/doi.org\/10.1056\/nejmoa1700518","journal-title":"N Engl J Med"},{"issue":"4","key":"4388_CR31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00380-023-02339-5","volume":"39","author":"S Yamazoe","year":"2024","unstructured":"Yamazoe S, Imai H, Ogawa Y, Kano N, Murase Y, Mamiya K, Ikeda T, Hiramatsu K, Torii J, Kawaguchi K (2024A) The effect of off-label use of reduced-dose direct oral anticoagulants therapy in the treatment of pulmonary embolism comparable to standard-dose therapy. Heart Vessels 39(4):365\u2013372","journal-title":"Heart Vessels"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04388-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04388-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04388-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:05:15Z","timestamp":1771538715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04388-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4388"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04388-1","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}